Janux Therapeutics, Inc. Current ratio
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
| Current ratio | 0.1x | 5.0x | 29.5x | 20.1x | 26.8x | 59.2x |
Janux Therapeutics, Inc. (JANX) Current ratio comparison analysis
General
LTM Current ratio
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
JANX key stats
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 3.6 0.0% | 8.6 136.8% | 8.1 (6.1%) | 10.6 31.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.1 | 0.8 | 2.0 | 0.0 |
% margin | (0.0) 0.0% | (0.0) 0.0% | 3.5 96.9% | 7.8 90.2% | 6.1 75.8% | 10.6 100.0% |
| Operating Expenses | 3.8 | 4.8 | 36.6 | 75.7 | 81.1 | 109.4 |
| Research & Development Expenses (R&D) | 3.0 | 3.0 | 26.2 | 53.4 | 54.9 | 68.4 |
| Selling, General & Administrative Expenses (SG&A) | 0.8 | 1.8 | 10.3 | 22.3 | 26.1 | 41.0 |
% margin | (3.8) 0.0% | (4.8) 0.0% | (32.9) (905.4%) | (67.1) (779.0%) | (73.0) (902.9%) | (98.8) (933.6%) |
| Interest Income | 0.2 | 0.2 | 0.3 | 4.0 | 14.7 | 29.9 |
| Interest Expense | 0.2 | 0.2 | 0.0 | 4.0 | 0.0 | 0.0 |
| Pre-tax Income | (4.0) | (6.8) | (32.7) | (63.1) | (58.3) | (69.0) |
% effective tax rate | 0.2 (5.8%) | (1.5) 22.5% | (0.1) 0.3% | (8.9) 14.1% | 0.0 0.0% | 0.0 0.0% |
% margin | (4.2) 0.0% | (5.3) 0.0% | (32.6) (895.2%) | (54.2) (628.8%) | (58.3) (721.2%) | (69.0) (651.6%) |
| EPS | (0.10) | (0.13) | (0.79) | (1.31) | (1.32) | (1.28) |
| Diluted EPS | (0.10) | (0.13) | (0.79) | (1.31) | (1.32) | (1.28) |
% margin | (3.8) 0.0% | (4.8) 0.0% | (32.8) (902.3%) | (66.3) (769.3%) | (71.0) (878.7%) | (98.8) (933.6%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Janux Therapeutics, Inc.'s Current ratio?
As of today, Microsoft Corp's last 12-month Current ratio is 59.2x, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Current ratio for Janux Therapeutics, Inc. have been 33.8x over the past three years, and 26.2x over the past five years.
2) Is Janux Therapeutics, Inc.'s Current ratio Good?
As of today, Janux Therapeutics, Inc.'s Current ratio is 59.2x, which is higher than industry median of 4.6x. It indicates that Janux Therapeutics, Inc.'s Current ratio is Good.